Trisalus Life Sciences, Inc. ( (TLSI) ) has released its Q3 earnings. Here is a breakdown of the information Trisalus Life Sciences, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that integrates innovative delivery technology with standard-of-care therapies to improve outcomes for patients with solid tumors. The company is known for its proprietary Pressure-Enabled Drug Delivery (PEDD) technology and investigational immunotherapeutic, nelitolimod.
In its third-quarter 2025 earnings report, TriSalus Life Sciences reported a significant increase in revenue, reaching $11.6 million, which marks a 57% year-over-year growth. This growth is primarily attributed to the increased adoption of their TriNav product suite for liver embolization. The company also reaffirmed its full-year revenue growth guidance of at least 50%.
Key financial highlights include a gross margin of 84% and a reduction in quarterly cash burn by approximately 50%. The company also simplified its capital structure through a successful exchange offering of Series A Preferred stock. Additionally, TriSalus is advancing its clinical programs, including the completion of three PERIO clinical phase 1 dose escalation studies and the initiation of a clinical trial for genicular artery embolization as a potential treatment for knee osteoarthritis.
Despite the positive revenue growth, TriSalus reported a net loss attributable to common stockholders of $41.3 million for the third quarter, primarily due to the conversion of preferred stock to common stock. The company ended the quarter with $22.7 million in cash and cash equivalents, providing a sufficient runway to reach positive adjusted EBITDA.
Looking ahead, TriSalus Life Sciences remains committed to expanding the application of its PEDD technology and improving patient outcomes. The company is focused on building a data-driven case for its technology and exploring partnership opportunities for the development of nelitolimod, reflecting a strategic shift in its business operations.